Recently, Tiribelli et al showed that a combination of the EUTOS Score and BCR-ABLIS at 3 months identified a group of CML patients with a favorable response to imatinib, suggesting that a combination of independent parameters might better stratify patients.27 Therefore, we combined the WBC count at presentation and BCR-ABLIS at 3 months, which were the independent predictors with the highest HR. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.